ACADIA Pharmaceuticals, Inc. (ACAD)
18.74
+0.60
(+3.31%)
USD |
NASDAQ |
Nov 13, 16:00
18.75
+0.01
(+0.05%)
After-Hours: 19:59
ACADIA Pharmaceuticals Net Income (Quarterly) : 53.52M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 53.52M |
| June 30, 2026 | 31.50M |
| March 31, 2026 | 3.637M |
| December 31, 2025 | 273.57M |
| September 30, 2025 | 71.78M |
| June 30, 2025 | 26.67M |
| March 31, 2025 | 18.99M |
| December 31, 2024 | 143.74M |
| September 30, 2024 | 32.76M |
| June 30, 2024 | 33.39M |
| March 31, 2024 | 16.56M |
| December 31, 2023 | 45.80M |
| September 30, 2023 | -65.18M |
| June 30, 2023 | 1.114M |
| March 31, 2023 | -43.02M |
| December 31, 2022 | -41.72M |
| September 30, 2022 | -27.18M |
| June 30, 2022 | -34.01M |
| March 31, 2022 | -113.06M |
| December 31, 2021 | -43.09M |
| September 30, 2021 | -14.46M |
| June 30, 2021 | -43.87M |
| March 31, 2021 | -66.45M |
| December 31, 2020 | -66.76M |
| September 30, 2020 | -84.66M |
| Date | Value |
|---|---|
| June 30, 2020 | -42.14M |
| March 31, 2020 | -88.02M |
| December 31, 2019 | -53.04M |
| September 30, 2019 | -41.98M |
| June 30, 2019 | -54.94M |
| March 31, 2019 | -85.30M |
| December 31, 2018 | -65.49M |
| September 30, 2018 | -62.14M |
| June 30, 2018 | -63.27M |
| March 31, 2018 | -54.30M |
| December 31, 2017 | -68.87M |
| September 30, 2017 | -65.25M |
| June 30, 2017 | -67.44M |
| March 31, 2017 | -87.84M |
| December 31, 2016 | -78.70M |
| September 30, 2016 | -71.61M |
| June 30, 2016 | -71.32M |
| March 31, 2016 | -49.76M |
| December 31, 2015 | -45.78M |
| September 30, 2015 | -38.91M |
| June 30, 2015 | -39.38M |
| March 31, 2015 | -40.38M |
| December 31, 2014 | -28.37M |
| September 30, 2014 | -24.79M |
| June 30, 2014 | -21.50M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -109.97M |
| Arcturus Therapeutics Holdings, Inc. | -7.414M |
| ADMA Biologics, Inc. | 49.88M |
| Immunic, Inc. | -34.10M |
| Viking Therapeutics, Inc. | -183.19M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 342.29M |
| Total Expenses (Quarterly) | 288.77M |
| EPS Diluted (Quarterly) | 0.305 |
| Enterprise Value | 2.230B |
| Gross Profit Margin (Quarterly) | 89.75% |
| Profit Margin (Quarterly) | 15.64% |
| Earnings Yield | 11.23% |
| Operating Earnings Yield | 3.77% |
| Normalized Earnings Yield | 11.23 |